Arnhold LLC Purchases New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Arnhold LLC purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 9,190 shares of the medical equipment provider’s stock, valued at approximately $1,118,000.

A number of other institutional investors also recently modified their holdings of ZBH. Naples Money Management LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $35,000. Activest Wealth Management grew its holdings in shares of Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 275 shares during the last quarter. Peoples Bank KS bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at $48,000. Blue Trust Inc. grew its holdings in shares of Zimmer Biomet by 48.4% during the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 153 shares during the last quarter. Finally, Quent Capital LLC grew its holdings in shares of Zimmer Biomet by 21.6% during the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 92 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH stock traded down $1.43 during trading hours on Tuesday, reaching $120.28. The company had a trading volume of 1,428,306 shares, compared to its average volume of 1,445,902. The business has a fifty day moving average price of $125.83 and a 200-day moving average price of $119.92. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25. The firm has a market cap of $24.71 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 2.19 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same period in the previous year, the business posted $1.88 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is 19.63%.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of recent analyst reports. Raymond James raised their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Truist Financial raised their price target on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a report on Friday, February 9th. Evercore ISI raised their price target on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 9th. Finally, StockNews.com cut shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $139.39.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.70% of the stock is currently owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.